# Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

> **NCT04267393** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 124 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** BMS-986263
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04267393
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2023-08-16
- **Final completion:** 2024-02-09
- **Target enrollment:** 124 (ACTUAL)
- **Why stopped:** Trial terminated because of lack of efficacy in the short term acute phase.
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267393, "Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04267393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*